Zahra Bahadoran et al conducted a study to assess the association between serum zinc (SZn) concentration and fracture risk in postmenopausal women.
Women (n = 851) with a history of natural, premature, or surgical menopause who had completed data, including SZn concentrations at baseline, were included and followed through for the incidence of any fracture requiring inpatient care. Potential non-linear and dose–response associations between SZn and fracture risk were assessed using a restricted cubic spline model (RCS) in Cox regression with the likelihood ratio test (LRT). Multivariable Cox proportional hazard models were used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of fractures across the categories of SZn [< 86, 86–135 (as reference), and ≥ 135 μg/dL].
The key findings of the study were:
• During a median follow-up period of 8.8 years (interquartile range: 8.1–9.2 years), 4.3% of postmenopausal women (with a mean age of 61.4 +/- 8.6 years) experienced a new incident fracture.
• The mean of baseline SZn concentration was 113 +/- 39.3 μg/dL.
• The LRT indicated no significant non-linear association (P = 0.176) and no evidence of a dose–response relationship (P = 0.448) between SZn and fracture risk.
• Using the categorical approach, the multivariable-adjusted Cox model showed that postmenopausal women with SZn concentrations below 86 μg/dL had a significantly increased risk of fracture compared to those within the reference range (86–135 μg/dL), with an HR of 2.29 (95% CI = 1.02–5.16, P = 0.044).
• SZn concentrations exceeding the reference range (≥ 135 μg/dL) were not associated with risk of fractures (HR = 1.47, 95% CI = 0.61–3.58).
“In conclusion, this prospective study provides novel evidence linking suboptimal SZn concentrations to an increased risk of bone fractures in postmenopausal women, highlighting zinc status as a potentially modifiable risk factor in this high-risk population. The absence of a continuous dose–response association, together with the slight, nonsignificant increase in fracture risk at SZn concentrations above the reference range, suggests that while insufficient zinc clearly elevates risk and requires attention, excess zinc levels may also be potentially harmful.
These findings underscore the importance of maintaining zinc within the physiological reference range, indicating that routine dietary or supplemental zinc intake beyond physiological requirements may not confer additional benefit. These findings have significant clinical and public health implications, suggesting that assessment of zinc status and targeted zinc supplementation could be integrated into the management of osteoporosis and prevention of fractures for postmenopausal women. Given the high prevalence of zinc deficiency in postmenopausal women, zinc supplementation may serve as an effective strategy to support bone quality and reduce fracture risk” the authors opined.
Further reading:
Association between serum zinc concentration and fracture risk in postmenopausal women: a 9‑year cohort study Zahra Bahadoran et al Journal of Bone and Mineral Metabolism https://doi.org/10.1007/s00774-025-01645-4
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.